cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24474502.v1
title: Prognostic factors for pure ovarian immature teratoma and the role of adjuvant chemotherapy in stage I diseases

description: The prognostic factors for patients with pure ovarian immature teratoma (POIT) and the role of adjuvant chemotherapy in stage IA G2-G3 and IB-IC POIT remains controversial. We conducted a retrospective study of 155 POIT patients treated in our hospital between 2000 and 2022. The recurrence-free survival (RFS), disease-specific survival (DSS), and potential prognostic factors of POIT patients were evaluated. Subgroup analysis was conducted in stage I other than stage IA G1 POIT. The median age at diagnosis was 23.0 years (range: 4.0 − 39.0), and 126 (81.3%), 2 (1.3%), 26 (16.8%), and 1 (0.6%) patients had FIGO stage I, stage II, stage III, and stage IV disease, respectively. Twenty-three patients relapsed and five died of the diseases after a median follow-up of 7.6 years, with a 5-year RFS and DSS rate of 86.0% and 97.0%, respectively. Multivariate analysis showed that positive postoperative tumour markers (TM) were the risk factor for recurrence in the overall cohort (hazard ratio [HR] 4.058, 95% CI 1.175 − 14.019, <i>p</i> = 0.027) and subgroup (HR 10.237, 95% CI 2.175 − 48.179, <i>p</i> = 0.003), and FIGO stage II–IV was the only factor for DSS in overall cohort (HR 7.751, 95% CI 1.281 − 46.895, <i>p</i> = 0.026). In 110 patients subjected to subgroup analysis, 29 patients received surveillance without chemotherapy and 81 patients were administered adjuvant chemotherapy. Multivariate analysis revealed active surveillance significantly increased the recurrence rate (5-year RFS of 75.7% vs. 93.6%, HR 7.562, 95% CI 2.441 − 23.424, <i>p</i> &lt; 0.001) but not the death related to POIT (<i>p</i> = 0.338). Positive postoperative TM and FIGO stage II–IV were the prognostic factors for POIT. Active surveillance in stage I POIT of any grade may be practical for those with negative postoperative TM. Positive postoperative tumour markers and FIGO stage II–IV were the prognostic factors for pure ovarian immature teratoma. Active surveillance in stage I pure ovarian immature teratoma of any grade may be practical for those with negative postoperative tumor markers.
DOI: 10.6084/m9.figshare.25016511
title: Evidence and possible mechanism of <i>Scutellaria baicalensis</i> and its bioactive compounds for hepatocellular carcinoma treatment

description: Traditional Chinese medicines have been reported to have outstanding effects in the treating of hepatocellular carcinoma. <i>Scutellaria baicalensis</i> (<i>S. baicalensis</i>) has demonstrated anti-tumor, anti-angiogenic, and anti-inflammatory properties. Baicalein, wogonin, and baicalin are the main pharmacologically bioactive compounds of <i>S. baicalensis</i>. Eight electronic databases were searched to select articles published from their inception to 30 May 2022. For selected articles, clinical and preclinical data was obtained on the use of <i>S. baicalensis</i> and its bioactive compounds in hepatocellular carcinoma therapy. Statistical analyses were performed using RevMan version 5.3 and Stata software. Quality assessment of the studies was performed using Cochrane and Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE)’s risk of bias tools. Seven clinical and 17 preclinical <i>in vivo</i> studies along with 31 <i>in vitro</i> studies were included in this research. Meta-analysis showed that a Chinese herbal medicine preparation, with <i>S. baicalensis</i> as the sovereign herb, combined with Transcatheter arterial chemoembolization (TACE) or primary treatment, could lead to a significantly improved tumor objective response rate (Risk ratio (RR) = 1.57, 95% confidence interval (CI): [1.30, 1.90], <i>p</i> &lt; 0.00001). <i>Scutellaria baicalensis</i>-based extracts (standard mean difference (SMD) = –0.86, 95%CI: [–1.20, −0.53], <i>p</i> &lt; 0.00001), baicalein (SMD = –4.80, 95%CI: [–6.66, − 2.95], <i>p</i> &lt; 0.00001), baicalin (SMD = –2.28, 95%CI [–3.26, −1.30], <i>p</i> &lt; 0.00001) and wogonin (SMD = –1.41, 95%CI [–2.26, −0.57], <i>p</i> &lt; 0.00001) slowed tumor growth <i>in vivo</i>. These outcomes might be linked to the mechanism by which <i>S. baicalensis</i> promotes apoptosis, induces autophagy, and blocks the expression of vascular endothelial growth factor (<i>p</i> &lt; 0.05). Based on experimental and clinical evidence, we believe that <i>S. baicalensis</i> and its bioactive compounds have therapeutic potential and plausible mechanisms of action against hepatocellular carcinoma, in terms of efficacy and safety.
DOI: 10.6084/m9.figshare.25016511.v1
title: Evidence and possible mechanism of <i>Scutellaria baicalensis</i> and its bioactive compounds for hepatocellular carcinoma treatment

description: Traditional Chinese medicines have been reported to have outstanding effects in the treating of hepatocellular carcinoma. <i>Scutellaria baicalensis</i> (<i>S. baicalensis</i>) has demonstrated anti-tumor, anti-angiogenic, and anti-inflammatory properties. Baicalein, wogonin, and baicalin are the main pharmacologically bioactive compounds of <i>S. baicalensis</i>. Eight electronic databases were searched to select articles published from their inception to 30 May 2022. For selected articles, clinical and preclinical data was obtained on the use of <i>S. baicalensis</i> and its bioactive compounds in hepatocellular carcinoma therapy. Statistical analyses were performed using RevMan version 5.3 and Stata software. Quality assessment of the studies was performed using Cochrane and Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE)’s risk of bias tools. Seven clinical and 17 preclinical <i>in vivo</i> studies along with 31 <i>in vitro</i> studies were included in this research. Meta-analysis showed that a Chinese herbal medicine preparation, with <i>S. baicalensis</i> as the sovereign herb, combined with Transcatheter arterial chemoembolization (TACE) or primary treatment, could lead to a significantly improved tumor objective response rate (Risk ratio (RR) = 1.57, 95% confidence interval (CI): [1.30, 1.90], <i>p</i> &lt; 0.00001). <i>Scutellaria baicalensis</i>-based extracts (standard mean difference (SMD) = –0.86, 95%CI: [–1.20, −0.53], <i>p</i> &lt; 0.00001), baicalein (SMD = –4.80, 95%CI: [–6.66, − 2.95], <i>p</i> &lt; 0.00001), baicalin (SMD = –2.28, 95%CI [–3.26, −1.30], <i>p</i> &lt; 0.00001) and wogonin (SMD = –1.41, 95%CI [–2.26, −0.57], <i>p</i> &lt; 0.00001) slowed tumor growth <i>in vivo</i>. These outcomes might be linked to the mechanism by which <i>S. baicalensis</i> promotes apoptosis, induces autophagy, and blocks the expression of vascular endothelial growth factor (<i>p</i> &lt; 0.05). Based on experimental and clinical evidence, we believe that <i>S. baicalensis</i> and its bioactive compounds have therapeutic potential and plausible mechanisms of action against hepatocellular carcinoma, in terms of efficacy and safety.
DOI: 10.6084/m9.figshare.24201123
title: Prognostic role of the controlling nutritional status (CONUT) score in patients with biliary tract cancer: a meta-analysis

description: Previous reports have not reached consistent results regarding the prognostic significance of the controlling nutritional status (CONUT) score in biliary tract cancer (BTC). Therefore, the present meta-analysis was conducted to investigate the precise role of the CONUT score in predicting the prognosis of BTC. Electronic platforms including Web of Science, PubMed, Cochrane Library, and Embase were comprehensively searched up to May 2, 2023. We also determined combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the role of the CONUT score in predicting the prognosis of patients with BTC. Ten studies involving 1,441 patients were included in the present study. Nine studies treated patients with surgical resection, and one study used percutaneous transhepatic biliary stenting (PTBS) plus 125I seed intracavitary irradiation. Based on the combined data, a higher CONUT score significantly predicted dismal overall survival (OS) (HR = 1.94, 95%CI = 1.41–2.66, <i>p</i> &lt; 0.001), inferior recurrence-free survival (RFS) (HR = 1.79, 95%CI = 1.48–2.17, <i>p</i> &lt; 0.001) in BTC, and low differentiation (OR = 1.57, 95%CI = 1.15–2.14, <i>p</i> = 0.004). Nonetheless, the CONUT score was not related to sex, lymph node metastasis, microvascular invasion, perineural invasion, distant metastasis, TNM stage, or tumor number in patients with BTC. Higher CONUT scores significantly predicted worse OS and RFS in patients with BTC. Moreover, BTC patients with high CONUT scores tended to have poor tumor differentiation. The CONUT score could help clinicians stratify high-risk patients with BTC and devise individualized treatment plans. As far as we know, this study is the first to analyze whether pretreatment CONUT is significant for predicting the prognosis of BTC. A high CONUT significantly predicted worse OS and RFS in BTC patients. CONUT could help clinicians stratify high-risk BTC patients and devise individualized treatment plans.
DOI: 10.6084/m9.figshare.24569960
title: Mechanisms of resveratrol against diabetic wound by network pharmacology and experimental validation

description: Resveratrol (RSV) that possesses anti-oxidative, anti-inflammatory, and pro-angiogenic effects is an effective drug for diabetic wound (DW), while its pharmacological mechanism remains to be elucidated. In this study, we apply network pharmacology and experimental validation approach to reveal the potential mechanism of RSV against DW. We obtained potential targets for RSV and DW from the publicly available database. Using interaction networks and conducting GO and KEGG pathway enrichment analyses, we constructed target-pathway networks to explore the relationship between RSV and DW. To validate the pharmacological mechanism of RSV, we induced the DW model. Ninety overlapped targets between RSV and DW were obtained, and the hub genes of the PPI network included <i>TNF</i>, <i>IL-6</i>, <i>CASP3</i>, <i>MAPK3</i>, <i>VEGFA</i>, <i>IL-1β</i>, <i>AKT1</i>, and <i>JUN</i>. Based on target-pathway networks, the AGE-RAGE signalling pathway was involved in the RSV treatment of DW. Furthermore, <i>in vivo</i> experiments revealed that RSV significantly promoted wound healing in diabetic mice and attenuated the expression of pro-inflammatory cytokines in wound tissue. Meanwhile, RSV could inhibit the AGE-RAGE signalling pathway and thus reduce the activation of NF-κB. This study initially revealed the biological mechanism of RSV for treating DW through multi-target and multi-pathway. AGE-RAGE, FoxO, MAPK, PI3K-AKT and other signalling pathways may be the main pathways of RSV in treating DW. RSV reduces the inflammatory response by inhibiting the AGE-RAGE signalling pathway, which in turn promotes DW healing.
DOI: 10.6084/m9.figshare.24569960.v1
title: Mechanisms of resveratrol against diabetic wound by network pharmacology and experimental validation

description: Resveratrol (RSV) that possesses anti-oxidative, anti-inflammatory, and pro-angiogenic effects is an effective drug for diabetic wound (DW), while its pharmacological mechanism remains to be elucidated. In this study, we apply network pharmacology and experimental validation approach to reveal the potential mechanism of RSV against DW. We obtained potential targets for RSV and DW from the publicly available database. Using interaction networks and conducting GO and KEGG pathway enrichment analyses, we constructed target-pathway networks to explore the relationship between RSV and DW. To validate the pharmacological mechanism of RSV, we induced the DW model. Ninety overlapped targets between RSV and DW were obtained, and the hub genes of the PPI network included <i>TNF</i>, <i>IL-6</i>, <i>CASP3</i>, <i>MAPK3</i>, <i>VEGFA</i>, <i>IL-1β</i>, <i>AKT1</i>, and <i>JUN</i>. Based on target-pathway networks, the AGE-RAGE signalling pathway was involved in the RSV treatment of DW. Furthermore, <i>in vivo</i> experiments revealed that RSV significantly promoted wound healing in diabetic mice and attenuated the expression of pro-inflammatory cytokines in wound tissue. Meanwhile, RSV could inhibit the AGE-RAGE signalling pathway and thus reduce the activation of NF-κB. This study initially revealed the biological mechanism of RSV for treating DW through multi-target and multi-pathway. AGE-RAGE, FoxO, MAPK, PI3K-AKT and other signalling pathways may be the main pathways of RSV in treating DW. RSV reduces the inflammatory response by inhibiting the AGE-RAGE signalling pathway, which in turn promotes DW healing.
DOI: 10.6084/m9.figshare.24201123.v1
title: Prognostic role of the controlling nutritional status (CONUT) score in patients with biliary tract cancer: a meta-analysis

description: Previous reports have not reached consistent results regarding the prognostic significance of the controlling nutritional status (CONUT) score in biliary tract cancer (BTC). Therefore, the present meta-analysis was conducted to investigate the precise role of the CONUT score in predicting the prognosis of BTC. Electronic platforms including Web of Science, PubMed, Cochrane Library, and Embase were comprehensively searched up to May 2, 2023. We also determined combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the role of the CONUT score in predicting the prognosis of patients with BTC. Ten studies involving 1,441 patients were included in the present study. Nine studies treated patients with surgical resection, and one study used percutaneous transhepatic biliary stenting (PTBS) plus 125I seed intracavitary irradiation. Based on the combined data, a higher CONUT score significantly predicted dismal overall survival (OS) (HR = 1.94, 95%CI = 1.41–2.66, <i>p</i> &lt; 0.001), inferior recurrence-free survival (RFS) (HR = 1.79, 95%CI = 1.48–2.17, <i>p</i> &lt; 0.001) in BTC, and low differentiation (OR = 1.57, 95%CI = 1.15–2.14, <i>p</i> = 0.004). Nonetheless, the CONUT score was not related to sex, lymph node metastasis, microvascular invasion, perineural invasion, distant metastasis, TNM stage, or tumor number in patients with BTC. Higher CONUT scores significantly predicted worse OS and RFS in patients with BTC. Moreover, BTC patients with high CONUT scores tended to have poor tumor differentiation. The CONUT score could help clinicians stratify high-risk patients with BTC and devise individualized treatment plans. As far as we know, this study is the first to analyze whether pretreatment CONUT is significant for predicting the prognosis of BTC. A high CONUT significantly predicted worse OS and RFS in BTC patients. CONUT could help clinicians stratify high-risk BTC patients and devise individualized treatment plans.
DOI: 10.6084/m9.figshare.23916172
title: Novel applications of histopathological markers to distinguish prognostic subgroups in colorectal adenocarcinoma

description: To explore the novel applications of histological factors by stratifying the prognostic markers of the overall CRC patients in subgroups. A total of 17 histopathological and molecular factors were retrospectively collected and systematically analyzed for the prediction of CRC prognosis in the overall and stratified subgroups by using the Kaplan-Meier curve analysis as well as the Cox regression test. The χ<sup>2</sup> test was used to analyze the correlation of the prognostic markers with other factors. The histopathological markers including the lymph node metastasis (LNM), perineural/venous invasion (PVI), TNM stage, the local recurrence or distant metastasis after surgery (R/M) and the molecular markers Ki-67 expression as well as KRAS mutation were identified to be the independent prognostic biomarkers in the overall CRC. The differential prognosis of LNM was found to be significant in age, tumor site, histological classification (histo_classification), cell differentiation, and KRAS/NRAS/BRAF (KNB) mutation stratified subgroups. The PVI was discovered to differently predict survival for patients in age, histo_classification, differentiation, and R/M stratified subgroups. Same as LNM and PVI, TNM was also found to demonstrate differential prognosis in age, tumor site, histo_classification, differentiation, R/M status and KRAS/KNB mutation stratified subgroups. More importantly, R/M was firstly identified not to be terrible for patients in age, histo_classification, LNM, TNM, Ki-67, and KRAS/KNB stratified subgroups. Besides, KRAS mutation was innovatively found to show differential prognosis in age, differentiation, and LNM stratified subgroups. The stratification analyses of prognostic markers in CRC patients indicate novel applications of the above histopathological and molecular markers in clinic and the findings provide new insights into future investigations of precision pathology. The pathological markers LNM, PVI, TNM stage, R/M, the histological marker Ki-67 expression and the molecular marker KRAS mutation are all the early biomarkers capable of independently predicting the 2-year survival rate for CRC.Differential prognosis of the histopathological and molecular markers is commonly found in age, tumor site, differentiation, histological type, LNM, TNM, and R/M stratified CRC subgroups. The pathological markers LNM, PVI, TNM stage, R/M, the histological marker Ki-67 expression and the molecular marker KRAS mutation are all the early biomarkers capable of independently predicting the 2-year survival rate for CRC. Differential prognosis of the histopathological and molecular markers is commonly found in age, tumor site, differentiation, histological type, LNM, TNM, and R/M stratified CRC subgroups.
DOI: 10.6084/m9.figshare.23916172.v1
title: Novel applications of histopathological markers to distinguish prognostic subgroups in colorectal adenocarcinoma

description: To explore the novel applications of histological factors by stratifying the prognostic markers of the overall CRC patients in subgroups. A total of 17 histopathological and molecular factors were retrospectively collected and systematically analyzed for the prediction of CRC prognosis in the overall and stratified subgroups by using the Kaplan-Meier curve analysis as well as the Cox regression test. The χ<sup>2</sup> test was used to analyze the correlation of the prognostic markers with other factors. The histopathological markers including the lymph node metastasis (LNM), perineural/venous invasion (PVI), TNM stage, the local recurrence or distant metastasis after surgery (R/M) and the molecular markers Ki-67 expression as well as KRAS mutation were identified to be the independent prognostic biomarkers in the overall CRC. The differential prognosis of LNM was found to be significant in age, tumor site, histological classification (histo_classification), cell differentiation, and KRAS/NRAS/BRAF (KNB) mutation stratified subgroups. The PVI was discovered to differently predict survival for patients in age, histo_classification, differentiation, and R/M stratified subgroups. Same as LNM and PVI, TNM was also found to demonstrate differential prognosis in age, tumor site, histo_classification, differentiation, R/M status and KRAS/KNB mutation stratified subgroups. More importantly, R/M was firstly identified not to be terrible for patients in age, histo_classification, LNM, TNM, Ki-67, and KRAS/KNB stratified subgroups. Besides, KRAS mutation was innovatively found to show differential prognosis in age, differentiation, and LNM stratified subgroups. The stratification analyses of prognostic markers in CRC patients indicate novel applications of the above histopathological and molecular markers in clinic and the findings provide new insights into future investigations of precision pathology. The pathological markers LNM, PVI, TNM stage, R/M, the histological marker Ki-67 expression and the molecular marker KRAS mutation are all the early biomarkers capable of independently predicting the 2-year survival rate for CRC.Differential prognosis of the histopathological and molecular markers is commonly found in age, tumor site, differentiation, histological type, LNM, TNM, and R/M stratified CRC subgroups. The pathological markers LNM, PVI, TNM stage, R/M, the histological marker Ki-67 expression and the molecular marker KRAS mutation are all the early biomarkers capable of independently predicting the 2-year survival rate for CRC. Differential prognosis of the histopathological and molecular markers is commonly found in age, tumor site, differentiation, histological type, LNM, TNM, and R/M stratified CRC subgroups.
DOI: 10.6084/m9.figshare.23937151
title: Combined proteomics and transcriptomics identifies serpin family C member 1 associated protein as a biomarker of endometriosis

description: To explore potential biomarkers indicating endometriosis (EM). A proteomics method and combined quantitative transcriptomics were adopted to highlight markers in the EM. Venn analysis was used to integrate the ribonucleic acid sequencing (RNA-seq) and protein profiles. Promising candidate markers were tested by enzyme-related immunosorbent assay. A sum of 979 mRNAs and 39 proteins were tested to be significantly differentially expression in the standard cluster compared with the EM cluster. Venn analysis showed a filtered signature of only two down-regulated molecules in the EM group, i.e. fetuin B (FETUB) and serpin family C member 1 (SERPINC1); the latter showed a big variance between the control category and the EM set in the authentication test. SERPINC1 may be a useful possible biomarker for the analysis of EM.
DOI: 10.6084/m9.figshare.23937151.v1
title: Combined proteomics and transcriptomics identifies serpin family C member 1 associated protein as a biomarker of endometriosis

description: To explore potential biomarkers indicating endometriosis (EM). A proteomics method and combined quantitative transcriptomics were adopted to highlight markers in the EM. Venn analysis was used to integrate the ribonucleic acid sequencing (RNA-seq) and protein profiles. Promising candidate markers were tested by enzyme-related immunosorbent assay. A sum of 979 mRNAs and 39 proteins were tested to be significantly differentially expression in the standard cluster compared with the EM cluster. Venn analysis showed a filtered signature of only two down-regulated molecules in the EM group, i.e. fetuin B (FETUB) and serpin family C member 1 (SERPINC1); the latter showed a big variance between the control category and the EM set in the authentication test. SERPINC1 may be a useful possible biomarker for the analysis of EM.